| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30de88a14864b86592d41e6d5829c90d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3768003eb0a482ddf4d108fb920d6bb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
2013-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_285ddcc22ad5856ed457dca2f6f648fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8d9015875a31a554ca080c3f507f817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acebd53a95bc6e3d835697bb0d906292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_febe113902521134e00c7d3b23e9087c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03d79dd89a7fa3d077f8692ec50956d3 |
| publicationDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015218539-A1 |
| titleOfInvention |
Methods of using the calcineurin a variant cnab1 for the treatment of cardiac hypertrophy |
| abstract |
The present invention relates to an activator of the calcineurin subunit A β1 isofomi (C n A β1 ) or of the C-terminal domain of the calcineurin subunit Aβ 1 isofomi (C n Aβ 1 ) for the production of a medicament for the modulation of myocardial growth without adversely affecting contractile function. |
| priorityDate |
2012-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |